Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The G-BA Innovation Committee published funding priorities in Germany

On March 22, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities for projects on new forms of care (for single-stage process – open topic and for two-stage process – nine topics).

Due to the change caused by the Digital Act, which will soon come into force, a distinction is made between single- and two-stage funding procedures and (in the one-stage funding process) short and long project durations.

For a single-stage funding procedure (open topic), a distinction is made between a single-stage, short funding process (project duration up to 24 months) and a single-stage, long funding process (project duration usually from 36 up to 48 months):

  • Those interested in the single-stage, long funding process can apply until June 11, 2024. The Innovation Committee is expected to decide on the applications in the fourth quarter of 2024;
  • Those interested in the short, single-stage process can submit their applications on an ongoing basis - the Innovation Committee will decide on funding at regular intervals until the funds available within this process in the respective financial year (20 million euros) have been exhausted.

The topic-specific funding announcement in the two-stage process includes the following topics on new forms of care:

  • Oral health models for people in need of care and people with disabilities;
  • Outpatient health care;
  • Further development of cross-sector care facilities and supply networks;
  • Digital support concepts to strengthen accessibility in healthcare;
  • Domestic and sexual violence – care and prevention;
  • Data and algorithm-based decisions in general practice – new care concepts to strengthen guideline-based care;
  • Improving care processes in emergency services and emergency and acute care;
  • Improving care processes through data-based need recognition and design of care paths;
  • Care models to strengthen nicotine and tobacco cessation.

Applications for project funding that cannot be assigned to any of the topic areas can be submitted via the open-topic funding announcement.

Those interested in the two-stage process can apply with an idea sketch by May 22, 2024. The essential content of the planned new form of care should be presented in the idea sketch. The Innovation Committee is expected to decide in the fourth quarter of 2024 which idea sketches will be selected to develop a full application. The concept development phase will be funded for up to 6 months with a funding amount of up to €75,000.

The project management agency German Aerospace Center (Deutsches Zentrum für Luft- und Raumfahrt; DLR) is offering an information event for those interested in funding. The focus is on the requirements for the applications. The approximately one-hour web seminar will take place on April 11, 2024, at 11 a.m. Registration is not required.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.